Replies to post #248075 on Biotech Values

[vinmantoo]

Yes. Several have pointed to September-ish. I personally think that while possible, it is optimistic (early).

Phase 3 trials for EDP-235 needs to be started by late fall to early winter to be ready for a likely surge of cases then, well assuming Covid becomes more of a seasonal disease like influenza and RSV. To be ready, you know ENTA has been/is engaged with the FDA to lay out plans for the trials so they will get a decent handle on the costs. A partnership needs to be in place by then. If ENTA isn't finding the kind of terms they deem acceptable then they will have to considered running it alone. I know that isn't what they or I want as it is a bigger risk, but if it has to be done, then so be it.